GMB-475 |
Catalog No.GC36167 |
Le GMB-475 est un dégradeur de la tyrosine kinase BCR-ABL1 basé sur PROTAC, surmontant la résistance aux médicaments dépendante de BCR-ABL1. GMB-475 cible la protéine BCR-ABL1 et recrute la ligase E3 Von Hippel Lindau (VHL), entraÎnant l'ubiquitination et la dégradation subséquente de la protéine de fusion oncogène.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2490599-18-1
Sample solution is provided at 25 µL, 10mM.
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcomes BCR-ABL1-dependent drug resistance, targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein[1].
[1]. Burslem GM, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Res. 2019 Jul 16. pii: canres.1236.2019.
Average Rating: 5
(Based on Reviews and 16 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *